top of page

World Preclinical Congress

June 17-20, 2019. Boston, MA


Meet Us at WPC2019 and See How NeuCyte can Help Accelerate Your CNS Drug Discovery,

Efficacy and Safety Assessment

Booth 233

Join our scientific presentations 

Beyond iPSC Based Disease Models:

A Translatable Drug Discovery Platform for Status Epilepticus

Epilepsy is a common neurological disorder characterized by recurrent spontaneous seizures. About 30% of patients do not respond or develop resistance to available anti-epileptic drug treatments. The establishment of more translatable human cell-based assays can address the unmet need for new therapy strategies by complementing pre-clinical drug development to increase success rates in human patients. NeuCyte has built an iPSC-derived neural in vitro platform with complex electrophysiology-based phenotypic readouts to evaluate the efficacy of novel compounds and approved AEDs for the treatment of Status Epilepticus.

Date: June 18th

Time: 2:10pm

Room: Cityview 1

small-head shot_DH.jpg

Daniel Haag, PhD

CSO and Co-Founder, NeuCyte

Overcoming Challenges in CNS Drug Discovery through Developing Translatable iPSC-derived Cell-Based Assays

 Using direct reprogramming of iPSCs to generate defined human neural tissue, NeuCyte developed cell-based assays with complex neuronal structure and function readouts for versatile pre-clinical applications. Focusing on electrophysiological measurements, we demonstrate the capability of this approach to identify adverse neuroactive effects, evaluate compound efficacy, and serve phenotypic drug discovery.

Date: June 20th

Time: 1:00pm

Room: Harborview 1

Jonathan .jpeg

Jonathan Dávila, PhD

CTO and Co-Founder, NeuCyte

View our Scientific Poster

Implementation of Human iPSC-derived Neural Cultures in CNS Drug Discovery

June 18-20

bottom of page